Related Experiment Video
Updated: May 29, 2026
06:10
Three Strategies to Induce Neurotrophic Keratitis and Nerve Regeneration in Murine Cornea
Published on: December 8, 2023
Triple therapy for corneal neovascularization: a case report.
Daniele Veritti1, Stefano Vergallo, Paolo Lanzetta
1Department of Ophthalmology, University of Udine, Udine - Italy.
European Journal of Ophthalmology
|September 20, 2011
Summary
Triple therapy combining photodynamic therapy with verteporfin, bevacizumab, and triamcinolone acetonide effectively treated corneal neovascularization. This approach offers a promising solution for patients experiencing graft failure due to new blood vessel growth.
Area of Science:
- Ophthalmology
- Regenerative Medicine
Background:
- Corneal neovascularization (CNV) is a significant complication following corneal graft failure, often leading to poor visual outcomes.
- Current treatments for CNV are limited in efficacy and can have adverse effects.
Observation:
- A single patient with extensive deep and superficial CNV secondary to graft failure was treated with a novel triple therapy.
- The therapy involved same-day administration of subconjunctival bevacizumab, subconjunctival triamcinolone acetonide, and photodynamic therapy with verteporfin.
Findings:
- Complete angiographic regression of new corneal vessels was observed within 7 days post-treatment.
- While a minor recurrence was noted at 3 months, a repeat of the triple therapy resulted in no detectable CNV for the entire 6-month follow-up period.
Implications:
- This triple therapy regimen demonstrates potential as an effective treatment for challenging cases of corneal neovascularization.
- Further investigation and larger studies are warranted to confirm the safety and efficacy of this combination therapy in a broader patient population.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...